All Drug Targets articles – Page 25
-
NewsNew molecule disrupts pathways that promote cancer growth
Researchers have discovered a molecule that binds to a cancer cell protein, stopping growth of breast and ovarian tumours.
-
NewsPulmonary ionocytes: unexpected discovery has implications for CF
Researchers found surprising function of pulmonary ionocytes which may affect how cystic fibrosis drugs work.
-
ArticleMicrobiotica: transforming medicine with microbiome magic
In this interview, Anne Neville, Director at Microbiotica, elaborates on the significance of the Microbiotica Culture Collection (MCC) and Microbiotica Reference Genome Database (MRGD), which are fundamental to the development of live biotherapeutic medicines.
-
ArticleEmotional scars: stigma with female adult acne
New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany, has highlighted a previously underestimated aspect of acne's impact on individuals: its profound influence on social perception.
-
ArticlePatient-derived organoids in disease modelling
In an exclusive interview with Nikki Carter at Molecular Devices, we explore the the power of patient-derived organoids (PDOs) in drug discovery.
-
ArticlePossible adulticidal drugs for Onchocerca volvulus
This article discusses the need for adulticidal drugs to treat Onchocerca volvulus infections, a parasite causing onchocerciasis (river blindness), as the current treatment with ivermectin and surgery presents challenges for affected communities. It highlights research findings on the potential of analgesic medicines to target adult worms and emphasises the importance ...
-
ArticleAddressing increasingly resistant drugs by infectious agents
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
-
NewsConversations about the NHS: a bold prescription for it’s future
As the NHS celebrates its 75th anniversary, healthcare leaders, policymakers, and practitioners have been sharing their innovative ideas on how to reshape and safeguard its future.
-
WebinarSH2 domains as a target class in cancer and inflammation
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
-
ArticleUnleashing the power of AI in target discovery and resilience against disease
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting ...
-
ArticleTargeted protein degradation: turning undruggable targets into druggable targets
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation, ...
-
ArticleThe promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
-
ArticleThe evolution and promise of gene therapies
Dr David Baram from gene therapy company EmendoBio provides a snapshot of the history of therapeutic genetic engineering.
-
Whitepaperebook: Fluorescence polarization assays
This ebook outlines the basics of fluorescence polarization and discusses the advantages and limitations of FP-based biochemical assays.
-
Whitepaperebook: Choosing the right assay for PARP
This eBook describes different types of assays used to evaluate PARP activity and screening for specific inhibitors.
-
ArticleRNA processing in health and disease: challenges and opportunities of the field
In this interview, Sam Hasson, Senior Director at Rgenta Therapeutics, shares his journey in drug discovery, from graduate school to industry, and his current work developing small molecule therapeutics to target RNA processing. He discusses the challenges and opportunities in the field of RNA-centric drug discovery and highlights the potential ...
-
WhitepaperBrochure: Overcome roadblocks in your PROTAC characterizations with Dianthus
Learn how Dianthus resolves common challenges you face during the characterization of PROTAC binary and ternary complexes and the determination of cooperativity.
-
NewsNew method of designing drugs without side effects
Japanese researchers now reveal a new way of activating GPCR by triggering shape changes in the intracellular region of the receptor. This new process can help researchers design drugs with fewer or no side effects.
-
ArticlePromising human antibodies fighting SARS-CoV-2
Scientists have discovered that a vaccinated San Diego resident has produced antibodies that are effective against multiple variants of SARS-CoV-2, including Omicron. The research also identified three antibodies that can neutralise the virus, giving new insights into different binding mechanisms with the SARS-CoV-2 spike protein. The findings could help to ...
-
VideoVideo: Using luciferase reporter cell lines for HTS readouts
This video reviews the uses and advantages of reporter cell lines in the context of cellular research and drug discovery.